DexCom, Inc. (NASDAQ:DXCM) Receives Average Recommendation of “Moderate Buy” from Brokerages

Shares of DexCom, Inc. (NASDAQ:DXCM) have been given a consensus rating of “Moderate Buy” by the twenty-seven analysts that are currently covering the stock, MarketBeat.com reports. Two research analysts have rated the stock with a sell recommendation, four have issued a hold recommendation, nineteen have assigned a buy recommendation and two have given a strong buy recommendation to the company. The average 12-month target price among analysts that have issued ratings on the stock in the last year is $86.3043.

DXCM has been the topic of several recent analyst reports. UBS Group cut their target price on DexCom from $106.00 to $95.00 and set a “buy” rating on the stock in a research note on Monday, November 3rd. Cowen reaffirmed a “buy” rating on shares of DexCom in a research report on Friday, October 24th. Mizuho raised their price objective on shares of DexCom from $75.00 to $78.00 and gave the stock an “outperform” rating in a report on Wednesday, December 17th. The Goldman Sachs Group reduced their target price on shares of DexCom from $104.00 to $89.00 and set a “buy” rating for the company in a report on Wednesday, October 1st. Finally, Canaccord Genuity Group set a $99.00 price target on shares of DexCom and gave the stock a “buy” rating in a research report on Friday, October 31st.

DexCom Trading Up 0.4%

Shares of DXCM stock opened at $69.54 on Friday. The business has a 50-day moving average of $65.03 and a 200 day moving average of $71.55. The company has a debt-to-equity ratio of 0.45, a current ratio of 1.56 and a quick ratio of 1.38. DexCom has a 1-year low of $54.11 and a 1-year high of $93.25. The stock has a market capitalization of $27.12 billion, a PE ratio of 38.63, a P/E/G ratio of 1.25 and a beta of 1.48.

DexCom (NASDAQ:DXCM) last issued its quarterly earnings data on Thursday, October 30th. The medical device company reported $0.61 earnings per share for the quarter, topping analysts’ consensus estimates of $0.57 by $0.04. DexCom had a return on equity of 30.65% and a net margin of 15.96%.The firm had revenue of $1.21 billion for the quarter, compared to analyst estimates of $1.18 billion. During the same period last year, the company earned $0.45 EPS. The business’s quarterly revenue was up 21.6% compared to the same quarter last year. As a group, sell-side analysts anticipate that DexCom will post 2.03 earnings per share for the current year.

Insider Activity at DexCom

In other DexCom news, Director Richard Alexander Collins sold 3,948 shares of the business’s stock in a transaction dated Monday, November 10th. The stock was sold at an average price of $55.17, for a total transaction of $217,811.16. Following the completion of the sale, the director owned 37,994 shares of the company’s stock, valued at approximately $2,096,128.98. The trade was a 9.41% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director Bridgette P. Heller sold 1,012 shares of the firm’s stock in a transaction dated Wednesday, November 12th. The stock was sold at an average price of $58.07, for a total value of $58,766.84. Following the completion of the transaction, the director directly owned 27,031 shares in the company, valued at $1,569,690.17. This trade represents a 3.61% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders have sold 7,866 shares of company stock worth $448,177. Corporate insiders own 0.32% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of DXCM. Trust Co. of Vermont raised its holdings in DexCom by 14.8% during the fourth quarter. Trust Co. of Vermont now owns 1,122 shares of the medical device company’s stock valued at $74,000 after acquiring an additional 145 shares during the period. CVA Family Office LLC raised its stake in DexCom by 48.5% during the 4th quarter. CVA Family Office LLC now owns 450 shares of the medical device company’s stock valued at $30,000 after purchasing an additional 147 shares during the period. GAMMA Investing LLC raised its stake in DexCom by 2.5% during the 3rd quarter. GAMMA Investing LLC now owns 7,043 shares of the medical device company’s stock valued at $474,000 after purchasing an additional 169 shares during the period. IFP Advisors Inc lifted its holdings in DexCom by 24.7% in the 3rd quarter. IFP Advisors Inc now owns 900 shares of the medical device company’s stock worth $61,000 after purchasing an additional 178 shares in the last quarter. Finally, Inspire Investing LLC boosted its stake in DexCom by 6.1% in the 3rd quarter. Inspire Investing LLC now owns 3,139 shares of the medical device company’s stock worth $211,000 after purchasing an additional 180 shares during the period. Institutional investors own 97.75% of the company’s stock.

DexCom Company Profile

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.